Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price Competition and Innovation Act (BPCIA), post-grant disputes on biologic drug patents before the United States Patent and Trademark Office (USPTO), and proposed legislation and regulatory activities relating to biosimilars….
By: Fish & Richardson
Previous Story

Great Hearts America Announces Third-Party Data Breach at Veeya

Next Story

Ounce of Prevention: Is It Time to Perform a Security Risk Assessment?